Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Recommendation of "Moderate Buy" from Analysts

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the five analysts that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $66.00.

A number of brokerages have issued reports on CLDX. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research note on Wednesday. Cantor Fitzgerald reiterated an "overweight" rating and set a $67.00 price target on shares of Celldex Therapeutics in a report on Friday, March 22nd. TD Cowen initiated coverage on Celldex Therapeutics in a report on Wednesday, December 20th. They set an "outperform" rating for the company. Finally, Guggenheim raised their target price on Celldex Therapeutics from $72.00 to $90.00 and gave the company a "buy" rating in a report on Tuesday, February 27th.

Institutional Investors Weigh In On Celldex Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Point72 Hong Kong Ltd lifted its stake in Celldex Therapeutics by 57.9% in the first quarter. Point72 Hong Kong Ltd now owns 1,394 shares of the biopharmaceutical company's stock valued at $47,000 after buying an additional 511 shares during the last quarter. Allspring Global Investments Holdings LLC raised its stake in shares of Celldex Therapeutics by 70.9% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,941 shares of the biopharmaceutical company's stock worth $53,000 after purchasing an additional 805 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Celldex Therapeutics by 604.9% during the first quarter. Tower Research Capital LLC TRC now owns 2,178 shares of the biopharmaceutical company's stock worth $78,000 after purchasing an additional 1,869 shares during the last quarter. Cubist Systematic Strategies LLC raised its stake in shares of Celldex Therapeutics by 78.8% during the first quarter. Cubist Systematic Strategies LLC now owns 2,782 shares of the biopharmaceutical company's stock worth $100,000 after purchasing an additional 1,226 shares during the last quarter. Finally, Strs Ohio raised its stake in shares of Celldex Therapeutics by 92.9% during the fourth quarter. Strs Ohio now owns 2,700 shares of the biopharmaceutical company's stock worth $107,000 after purchasing an additional 1,300 shares during the last quarter.

Celldex Therapeutics Price Performance

NASDAQ CLDX traded up $1.03 during mid-day trading on Wednesday, hitting $39.63. The stock had a trading volume of 908,995 shares, compared to its average volume of 906,799. The firm's 50 day moving average is $41.98 and its 200 day moving average is $35.68. Celldex Therapeutics has a twelve month low of $22.11 and a twelve month high of $53.18. The stock has a market capitalization of $2.22 billion, a price-to-earnings ratio of -13.58 and a beta of 1.49.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.57) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.19. Celldex Therapeutics had a negative return on equity of 41.06% and a negative net margin of 2,054.46%. The firm had revenue of $4.13 million during the quarter, compared to the consensus estimate of $1.20 million. As a group, equities research analysts expect that Celldex Therapeutics will post -2.85 earnings per share for the current year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.